42nd Annual Macula Society Meeting
An event for ophthalmologists
42nd Annual Macula Society Meeting
An event for ophthalmologists
The Macula Society
3401 Enterprise Parkway Suite 310
US - OH 44122 Cleveland, Ohio
Tel.: +1 216 839 4949
Fax: +1 216 831 8221
-
Basisinformation
Datum13.02.2019 - 16.02.2019KongressBonita SpringsSpracheEnglischGebühren abgebührenfreiVeranstalterThe Macula Society
OrganisatorThe Macula Society
3401 Enterprise Parkway Suite 310
US - OH 44122 Cleveland, Ohio
Tel.: +1 216 839 4949
Fax: +1 216 831 8221 -
VERANSTALTUNGSORT
Hyatt Regency Coconut Point Resort and Spa
5001 Coconut Rd
FL 34134 Bonita Springs, US -
Programm
Wednesday, February 13, 2019 SESSION I - Diabetic Retinopathy 4:25 p.m Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Lucia Sobrin 4:29 p.m DRGen Study: Novel Genetic Variants in Extreme and Advanced (Proliferative)
Phenotypes of Diabetic RetinopathyArup Das 4:33 p.m. Risk Factors for Blindness in Patients With Diabetic Retinopathy: Lessons from
the AAO IRIS® RegistryRahul Khurana 4:37 p.m. Integrating Diabetic Eye Screening in a Haemodialysis Clinic Tunde Peto 4:41 p.m. Discussion of Previous Four Papers 4:45 p.m. Is Cataract Surgery a Risk Factor for the Incidence and Progression of Age-Related
Macular Degeneration and Diabetic Retinopathy?Tien Wong 4:54 p.m Diabetic Retinopathy Outcomes in Untreated Fellow Eyes of Patients Receiving
Ranibizumab in the RIDE/RISE Trials: The Road Less TraveledSophie Bakri 5:03 p.m. Patients Ultra-Responsive to Ranibizumab: Rates of >=4-Step Improvement in
Diabetic Retinopathy Severity in DRCR.net Protocol SSunir Garg 5:12 p.m. Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
with Intravitreal Aflibercept Injection: Results from the Phase 3 PANORAMA StudyDavid Brown 5:21 p.m. Optical Coherence Tomography Angiography Confirms that Intravitreal Anti-Vascular
Endothelial Growth Factor Can Diminish Signs of Diabetic Retinopathy Without
Reducing Non-PerfusionRamin Tadayoni 5:30 p.m Post Hoc Exploratory Analysis of Humphrey Visual Field Changes Through Five
Years in Eyes with Proliferative Diabetic RetinopathyMichael Elman 5:39 p.m Anti-Vascular Endothelial Growth Factor Therapy and Risk of Traction Retinal
Detachment in Eyes with Proliferative Diabetic Retinopathy: Post Hoc Analysis
of Five DRCR.net Randomized Clinical TrialsJustin Gottlieb 5:50 p.m. Introduction and Presentation of the Lawrence J. Singerman Medal
– Morton F. Goldberg, MD, FACS5:53 p.m. Award Recipient – Matthew D. Davis, MD (posthumous) SESSION II - Oncology 1 6:00 p.m. Intravitreal and Intra-Arterial Chemotherapy Drug Discovery Using a
Rabbit Model: Toxicity and Efficacy of Novel Compounds in VivoAnthony Daniels 6:04 p.m. Impact of Quantitative Genetic Ancestry on Precision Medicine in Uveal Melanoma J. William Harbour 6:08 p.m. Discussion of Previous Two Papers SESSION III - Imaging 6:15 p.m Ultra-Widefield Swept-Source OCT Imaging of Posterior Vitreous in Eyes with
High MyopiaKyoko Ohno-Matsui 6:24 p.m. Macular Pigment in Multiple Sclerosis Giovanni Staurenghi 6:33 p.m Quantifying Organelles Serving as Signal Sources for Imaging of the Human
Retinal Pigment Epithelium (RPE), via Volume Electron MicroscopyChristine Curcio 6:42 p.m Hyperspectral Autofluorescence (AF) Imaging for Detection of Drusen and
Sub Retinal Pigment Epithelium (subRPE) depositsR. Theodore Smith 6:46 p.m. Age-Related Changes in Autofluorescent (AF) Granules Accumulation of
the Human Retinal Pigment Epithelium (RPE)Thomas Ach 6:50 p.m. Diabetic Retinopathy Severity Level Assessment: Comparison of Seven-field
Fundus Photographs to Ultrawide-Field ImagingBarbara Blodi 6:54 p.m. Quantitative Comparison of Retinal Pixel Area Imaged by Ultra-Wide
Field Fundus CamerasAjay Kuriyan 6:58 p.m. Retinal Vascular Geometry and the Subsequent Risk of Diabetes Gavin Tan 7:02 p.m. Discussion of Previous Five Papers 7:07 p.m. Computational Fluid Dynamics Modeling of Diabetic Microaneurysms Identifies
Blood Flow Parameters Associated with Clot Presence and Local Neural
Retinal DisorganizationJennifer Sun 7:16 p.m. Topographic Variations of Choroidal Thickness in Healthy Eyes on Swept Source
Optical Coherence TomographyAlain Gaudric 7:20 p.m. Remodeling of Macular Vortex Veins in Pachychoroid Neovasculopathy Shoji Kishi 7:24 p.m. Dynamic Changes in Choroidal Conditions During Anti-Vascular Endothelial
Growth Factor Therapy in Polypoidal Choroidal VasculopathyYoko Ozawa 7:28 p.m. Discussion of Previous Three Papers 7:32 p.m. Adjourn Thursday, February 14, 2019 SESSION IV - OCT Angiography 7:30 a.m. Longitudinal Analaysis of Foveal Microvasculature Using OCT Angiography after
Rhegmatogenous Retinal Detachment SurgerySeung-Young Yu 7:39 a.m. How Abnormal is this FAZ? - Easier Detection of Diabetic FAZ Enlargement
Comparing En Face OCT Vascular Patterns to OCT AngiographyRichard Rosen 7:46 a.m. Quantitative OCT Angiography Analysis for Classification and Staging of
Non-Proliferative Diabetic RetinopathyJennifer Lim 7:53 a.m. Discussion of Previous Two Papers 7:57 a.m. 4D OCTA: Time-Resolved OCTA Can Visualize Chorioretinal Hemodynamics Nadia Waheed 8:06 a.m. Choriocapillaris Flow Impairment Surrounding Geographic Atrophy Correlates
with Disease ProgressionSriniVas Sadda 8:13 a.m Relationship Between Choriocapillaris Flow Deficits Around Geographic
Atrophy and Enlargement Rates Based on Swept Source OCT ImagingPhilip Rosenfeld 8:20 a.m. Discussion of Previous Two Papers 8:24 a.m. New Proposal for the Pathophysiology of Type 3 Neovascularization as
Based on Multimodal Imaging FindingsRichard Spaide 8:33 a.m Sensitivity of OCT Angiography in the Detection of Choroidal Neovascularization
in Wet AMD in Relation to Anatomical Features on SDOCTAude Ambresin 8:37 a.m. 3D Volumetric Analysis of Pigment Epithelial Detachment Progression in
Neovascular AMD using En Face OCT AngiographyDavid Sarraf 8:44 a.m. Volume-Rendered Projection-Resolved OCT Angiography: 3D Lesion Complexity Is
Associated With Therapy Response in Wet Age-Related Macular DegenerationAmani Fawzi 8:51 a.m. Discussion of Previous Three Papers 8:55 a.m. Introduction and Presentation of the Young Investigator Lecture and Award
– Eric H. Souied, MD, PhD8:58 a.m. Award Recipient and Lecture – Giuseppe Querques, MD, PhD 9:01 a.m. Discussion and Questions SESSION V - Neovascular AMD I 9:15 a.m. Prospective Trial Comparing Intravitreal Aflibercept Injection (IAI) Using a Modified
Treat-and-Extend (T&E) to Fixed Bi-Monthly Protocol for PCV: 6-Month OutcomesGemmy Cheung 9:24 a.m. Ten-Year Treatment Outcome of Polypoidal Choroidal Vasculopathy Using
Photodynamic Therapy and Anti-Vascular Endothelial Growth FactorWon Ki Lee 9:33 a.m. A Cost-Utility/Cost-Benefit Analysis of Bevacizumab, Ranibizumab & Aflibercept
Monotherapy for Treating Neovascular Age-Related Macular Degeneration (NVAMD)Gary Brown 9:37 a.m. Association Between Early Vision-Related Quality of Life Outcomes and Anatomic
Dryness Response in Neovascular Age-Related Macular Degeneration (nAMD):
A Post-Hoc Analysis of VIEW TrialsMichael Singer 9:41 a.m Higher-Order Optical Coherence Tomography (OCT) Fluid Burden Assessment: Analysis
From OSPREY Matched PhaseJustis Ehlers 9:45 a.m. Discussion of Previous Three Papers 9:48 a.m. Intravitreal Aflibercept in a Routine Treat and Extend Regimen in Treatment-Naïve Wet
AMD Patients: Prefinal 1-Year Outcome Data of the ASTERIA StudyStephan Michels 9:57 a.m. Brolucizumab Versus Aflibercept for Neovascular AMD: 48-Week Expanded Fluid
Analyses from the HAWK and HARRIER StudiesPeter Kaiser 10:06 a.m Intravitreal (IVT) Delivery of a Novel Depot Formulation of Sunitinib (GB-102) in
Patients With nAMD: Results of a Phase 1 First-in-Human StudyPravin Dugel 10:15 a.m. Port Delivery System With Ranibizumab (PDS) in Neovascular AMD: How Ladder
Phase 2 Results Informed Archway Phase 3 DesignDennis Marcus 10:24 a.m. Phase I/II Randomized Study of Proton Beam with Anti-VEGF For Exudative
Age-Related Macular Degeneration: Long-Term ResultsSusanna Park 10:30 a.m. Break SESSION VI - Deep Learning / Artificial Intelligence 10:50 a.m. Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color
Fundus PhotographsAnthony Adamis 10:59 a.m. Deep Generative Models Creating High-Resolution Synthetic Retinal Images and
Relevance to Humans and MachinesNeil M. Bressler, 11:08 a.m. DeepSeeNet: A Deep Learning Model for Automated Classification of Patient-Based
Age-Related Macular Degeneration Severity from Color Fundus Photographs.Emily Chew 11:17 a.m. Deep Learning in the Prediction of AMD Disease Progression Ursula Schmidt-Erfurth 11:26 a.m. Automated Segmentation of Lesions in Neovascular AMD Hyung Chan Kim 11:30 a.m. Prognostic Factors in Patients with Neovascular AMD or PCV from Clinical and OCT
Parameters using a Convolutional Neural NetworkHyewon Chung 11:34 a.m. Artificial Intelligence for Morphology-Based Function Prediction in Neovascular
Age-Related Macular DegenerationSteffen Schmitz-Valckenberg 11:38 a.m. Robustness of an Autonomous AI System for Detection of Diabetic Retinopathy Michael Abramoff 11:42 a.m. Artificial Intelligence Deep Learning System for Measurement of Retinal
Vascular CaliberCarol Cheung 11:46 a.m Discussion of Previous Five Papers 11:50 a.m. Introduction and Presentation of the J. Donald M. Gass Medal – Carol L. Shields,
MD, and Emily Y. Chew, MD11:53 a.m. Anthony AdamisAward Recipient – Usha Chakravarthy, MBBS, MD, PhD SESSION VII - Dry AMD 12:00 p.m. Longitudinal Changes in Rod Function in Intermediate Age-Related Macular
Degeneration With and Without Reticular PseudodrusenChi Luu 12:04 p.m. Classification of Intermediate Age-Related Macular Degeneration by Short-Term
Risk for Atrophy on Spectral Domain Optical Coherence TomographyEleonora Lad 12:08 p.m. The 9-Step Minnesota Grading System: A Model to Study Disease Pathogenesis Timothy Olsen 12:12 p.m. Müller Cells and Choriocapillaris in the Pathogenesis of Geographic Atrophy
Secondary to Age-Related Macular DegenerationElisabetta Pilotto 12:16 p.m. Taurocholic Acid Protects Against Age-Related Macular Degeneration in In Vitro Models Milam Brantley 12:20 p.m. Discussion of Previous Five Papers 12:25 p.m. Choroidal Vascular Changes in Atrophic AMD: Relationship with Disease
Stage and ARMS2 GenotypeRobert Mullins 12:34 p.m. Kamuvudines for Geographic Atrophy Jayakrishna Ambati 12:43 p.m. The Fate and Prognostic Implications of Cholesterol Crystals in Non-Neovascular
Age-Related Macular DegenerationK. Bailey Freund 12:52 p.m. Cuticular Drusen: The Nature of Phenotype 3 Lawrence Yannuzzi 1:01 p.m. Subthreshold Nanosecond Laser to Slow Progression of Intermediate Age-Related
Macular Degeneration: The LEAD Trial Secondary OutcomesRobyn Guymer 1:10 p.m. Photovoltaic Restoration of Central Vision in Patients with Geographic Atrophy José-Alain Sahel 1:15 p.m Young Member Mentor Lecture Program Friday, February 15, 2019 7:00 a.m. Business Meeting SESSION VIII - Neovascular AMD II 7:50 a.m. Topical Inhibition of Runx1 Reduces Choroidal Neovascularization in Mice Leo Kim 7:54 a.m. Anti-VEGF Monotherapy for Thick Submacular Hemorrhage Associated with Retinal
Pigment Epithelial Detachment in Age-Related Macular DegenerationJeffrey Gross 7:58 a.m. Time to Maximum Response in Eyes with Neovascular AMD Treated with Ranibizumab Demetrios Vavvas 8:02 a.m. Comparison of Intravitreal Silicone Oil Microdroplet Following Multiple Bevacizumab,
Ranibizumab and Aflibercept InjectionsJohn Thompson 8:06 a.m Discussion of Previous Four Papers 8:10 a.m Antagonism of Mineralocorticoids Inhibits Choroidal Neovascularization: Implication
for Wet AMDFrancine Behar-Cohen 8:19 a.m Human Plasma Metabolomics in Age-Related Macular Degeneration
– Meta-Analysis of Two Distinct CohortsJoan Miller 8:28 a.m. Is Drier Really Better in Neovascular Age-Related Macular Degeneration? Nancy Holekamp 8:37 a.m A “Real World” Analysis of Visual Acuity Outcomes in 49,485 Eyes Receiving
Anti-Vascular Endothelial Growth Factor Therapy for Neovascular AMDThomas Ciulla 8:46 a.m Real-World Analysis of Injection Frequency Following Wet AMD Diagnosis
According to Baseline Visual AcuityJudy Kim 8:55 a.m. Analysis of Anti-VEGF Injection Claims Data in Medicare Beneficiaries Following CATT Trial Paul Sternberg, Jr SESSION IX - Vitreo-Retinal Surgery 9:05 a.m. Central Retinal Artery Occlusion on Postoperative Day One after Vitreoretinal Surgery Harry Flynn 9:09 a.m. Rotation in Retinal Nerve Fiber Layer Peak after Epiretinal Membrane Removal Hyeong Gon Yu 9:13 a.m. Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study:
Five-Year FindingsStephen Kim 9:17 a.m. Posterior Vitreous Mobility Delineated by Tracking of Optical Coherence
Tomography Images in Eyes with Macular HolesKeisuke Mori 9:21 a.m. Clinical Characteristics, Risk Factors, and Surgical Outcomes of a Secondary
Macular Hole after VitrectomyMin Kim 9:25 a.m. Discussion of Previous Five Papers 9:29 a.m. Comparative Study of Peeled Internal Limiting Membrane (ILM) Reposition and
ILM Peeling in Idiopathic Macular Hole: A Randomized-Control TrialPeiquan Zhao 9:38 a.m. First Failed Macular Hole Surgery or Reopening of a Previously Closed Hole:
Do we Gain by Re-Operating? – A Systematic Review and Meta AnalysisNoemi Lois 9:47 a.m. Connecting the Surgeon to OCT Image Guidance for Vitreoretinal Surgery Cynthia Toth 9:56 a.m. Placing the Surgeon in the Center - Placing the Surgeon in the Center -
A Novel 3D Visualization Platform for Retina Surgery Providing Transparent
Display, Data Overlay and GuidanceAnat Loewenstein 10:05 a.m. Introduction and Presentation of the Paul Henkind Memorial Lecture and Award
- Sophie J. Bakri, MD10:08 a.m. Paul Henkind Memorial Lecture and Award - Jose S. Pulido, MD, MS, MBA, MPH 10:25 a.m. Break SESSION X - Diabetic Macular Edema 10:45 a.m. Müller Cells Activity is Restored and Retinal Inflammation Reduced by Subthreshold
Micropulse Laser Treatment of Human Diabetic Macular EdemaEdoardo Midena 10:49 a.m. OCT Angiography Detects Early Microvascular Changes after Subthreshold
Micropulse Laser in Diabetic Macular EdemaStela Vujosevic 10:53 a.m. Two-year Outcomes of Ranibizumab Treatment for Diabetic Macular Edema.
Data from the Fight Retinal Blindness! ProjectDaniel Barthelmes 10:57 a.m. Vision Threatening Complications in Patients with Diabetic Macular Edema:
A Post Hoc Analysis from the VISTA and VIVID TrialsIvan Suner 11:01 a.m. Discussion of Previous Four Papers 11:05 a.m. A 12-month Prospective Study to Evaluate the Efficacy of Treat and Extend Regimen (T&E)
of Intravitreal Aflibercept as a Second-Line Treatment for Diabetic Macular Edema (TADI Study)Itay Chowers 11:14 a.m. Observation Versus Treatment in Diabetic Macular Edema with Very Good Visual Acuity
– The OBTAIN StudyAdrian Fung 11:23 a.m. Relationship between Change in Visual Acuity and Change in Retinal Thickness during
Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept,
Bevacizumab or RanibizumabMathew MacCumber 11:27 a.m. Visual Acuity with Habitual Correction on an Early Treatment Diabetic Retinopathy
Study (ETDRS) Chart vs. Protocol Refraction on an Electronic ETDRS Chart in Eyes
with Diabetic Macular EdemaSusan Bressler 11:31 a.m. Long-Term Intraocular Pressure Outcomes in Patients Receiving the 0.2 ug/day Fluocinolone
Acetonide Intravitreal ImplantDaniel Roth 11:35 a.m. Discussion of Previous Three Papers 11:39 a.m. Suprachoroidal CLS-TA Plus Aflibercept Compared to Aflibercept Monotherapy for
Diabetic Macular Edema: Results of the Randomized Phase 2 TYBEE TrialCharles Wykoff 11:48 a.m. Dual Inhibition of Ang-2 and VEGF-A with Faricimab: Evidence for Increased Durability
from the BOULEVARD Phase 2 Trial for Diabetic Macular EdemaCaroline Baumal SESSION XI - Pediatric Retina and Inherited Retinal Diseases 12:00 p.m. Fluorescein Angiography Findings in Infants Treated With Intravitreal Bevacizumab
for Retinopathy of PrematurityG. Baker Hubbard, III 12:09 p.m. An Interesting Family with Achromatopsia J. Timothy Stout 12:18 p.m. Longitudinal Changes in Scotopic and Mesopic Macular Function as Assessed with
Microperimetry in Patients with Stargardt Disease – The SMART StudyHendrik Scholl 12:27 p.m. Complement C5 Inhibition as a Potential Treatment for Autosomal Recessive Stargardt
Disease (STGD1): Design of a Clinical Trial Assessing a Novel Treatment and
Primary Outcome MeasureChristine Kay 12:36 p.m. Extracellular Matrix Disorders and Inherited Retinal Dystrophies Isabelle Meunier 12:40 p.m. RDH12 Disease: A Severe Central Retinal Degeneration with Relatively
Spared Rod FunctionTomas Aleman 12:44 p.m. Disease Stage Classification of Choroideremia for Clinical Treatment Trials
and Clinical PracticePeter Francis 12:48 p.m. Optical Coherence Tomography Angiography Assessment of Neurovascular
Damage as Biomarker of Progression in Best DiseaseMaurizio Battaglia Parodi 12:52 p.m. Discussion of Previous Four Papers 1:00 p.m. Introduction and Presentation of the Arnall Patz Medal – Gregory S. Hageman, MD, PhD 1:03 p.m. Award Recipient – Mary Elizabeth Ruth Hartnett, MD, FACS, FARVO 1:15 p.m. Adjourn Saturday, February 16, 2019 SESSION XII - Neuroprotection, Gene Therapy, Regenerative Medicine 7:30 a.m VMD2 Promoter Shows Optimal Specificity and Expression of Protective
Rap1a in Retinal Pigment EpitheliumMary Elizabeth Hartnett 7:39 a.m. A New Approach to Ocular Gene Therapy: Evaluation of Suprachoroidal
Administration of Non-Viral DNA Nanoparticles in a Rabbit ModelSzilard Kiss 7:48 a.m. Progress Toward Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa Edwin Stone 7:57 a.m. Change in Legal Blindness Status During the Phase 3 Voretigene Neparvovec-rzyl
Study in Biallelic RPE65 Mutation–Associated Inherited Retinal DiseaseJulia Haller 8:06 a.m. Optogenetics for Vision Restoration Sai Chavala 8:15 a.m. Intraoperative Optical Coherence Tomographic Findings in Patients
Undergoing Ocular Gene Therapy SurgeryAndreas Lauer 8:19 a.m. Surgical Implantation and In-Vivo Degradation of Fibrin Scaffolds within the Subretinal Space Raymond Iezzi 8:23 a.m. In-Vivo Imaging of Cone Photoreceptor Transplantation Mandeep Singh 8:27 a.m. Neuroprotective Role of Hexokinase 2 in Photoreceptor Survival Cagri Besirli, 8:31 a.m. Discussion of Previous Four Papers 8:35 a.m. Introduction and Presentation of the W. Richard Green Lecture and Award
– Mary Elizabeth Ruth Hartnett, MD, FACS, FARVO8:38 a.m. W. Richard Green Lecture and Award – Paul S. Bernstein, MD, PhD 8:58 a.m. Introduction and Presentation of the Evangelos S. Gragoudas Lecture
and Award – Neil M. Bressler, MD9:01 a.m. Evangelos S. Gragoudas Recipient Lecture and Award – Daniel Shu Wei Ting, MD, PhD 9:05 a.m. Introduction and Presentation of the Lawrence J. Singerman Medal – Emily Y. Chew, MD 9:08 a.m. Award Recipient – Maureen G. Maguire, PhD, FARVO SESSION XIII - Oncology 2 9:15 a.m. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable
Cancer Targets (MSK-IMPACT) of Retinoblastoma TumorsJasmine Francis 9:19 a.m. Discussion of Previous Paper 9:21 a.m. Follow the Nevus: The Cost-Utility of Screening for Growth of Choroidal Nevi William Smiddy 9:30 a.m. Small Choroidal Melanoma Managed by Plaque Radiotherapy in 1780 Cases:
Visual Outcome and Millimeter Incremental Risk for MetastasisCarol Shields 9:39 a.m. Clinical Features and Survival Outcome of 1111 Patients with Choroidal
Metastasis Based on Primary Tumor OriginJerry Shields 9:48 a.m. Outcomes after Proton Irradiation for Patients Who are Eligible for
Investigational AU-011 TreatmentEvangelos Gragoudas 9:57 a.m. Aflibercept for Radiation Maculopathy (ARM Study): A Prospective, Randomized
Clinical Study with 2 year Outcome AnalysisTimothy Murray 10:10 a.m. Break SESSION XIV - Other Macular Diseases 10:30 a.m. Longitudinal Changes in Eyes with Hydroxychloroquine Retinal Toxicity Catherine Cukras 10:39 a.m. Topographic OCT Shows Limited Anatomic Recovery from Early
Hydroxychloroquine RetinopathyMichael Marmor 10:48 a.m. Association Between Industry Payments and Scholarly Impact Amongst
Retina Specialists and OphthalmologistsRon Adelman 10:52 a.m. Anti-Enolase Drusen as a Subtype of Autoimmune Retinopathy Susumu Ishida 10:56 a.m. Genes Associated with the Clinical Characteristics of Central Serous
ChorioretinopathyAkitaka Tsujikawa 11:00 a.m. Discussion of Previous Three Papers 11:03 a.m. Chronic Obstructive Sleep Apnea and Central Serous Chorioretinopathy:
A Significant Association and Possible MechanismSteven Schwartz 11:12 a.m. Bruch’s Membrane and Myopic Axial Elongation Jost Jonas 11:21 a.m. Exploring Retinal Mechanisms in Myopia: Photopic Electroretinogram
Parameters and a Common Myopia Susceptibility VariantOmar Mahroo 11:25 a.m. Digital Quantification of Metamorphopsia in Patients With Macular Disease:
A Pilot StudyAndrew Moshfeghi 11:29 a.m. Discussion of Previous Two Papers SESSION XV - Retinal Venous Occlusive Disease 11:32 a.m. Supernormal Flicker ERGs in Eyes with Central Retinal Vein Occlusion:
Clinical Characteristics, Prognosis, and Effects of Anti-VEGF AgentMineo Kondo 11:36 a.m. A Novel Contrast Sensitivity Testing Device as a New Clinical Endpoint for
Retinal Vein OcclusionJohn Miller 11:40 a.m Discussion of Previous Two Papers 11:42 a.m. Patient-Reported Visual Function Outcomes after Anti-VEGF Therapy for
Macular Edema due to CRVO or HRVO: Results from the SCORE2 TrialIngrid Scott 11:51 a.m. SD-OCT Predictors of Visual Outcomes after Ranibizumab Treatment for
Macular Edema due to Retinal Vein Occlusion in the SHORE StudyGlenn Yiu 12:00 p.m. Long Term Outcomes of Eyes with Macular Edema Secondary to CRVO
Treated with Intravitreal Bevacizumab. Real Life Experience of the
Pan American Collaborative Retina Study (PACORES) GroupLihteh Wu 12:09 p.m. Re-packaging Bevacizumab in 2-mL Glass Vials for Prolonged Sterility, Stability and Bio-activity Michael Ip SESSION XVI - Uveitis 12:20 p.m. Polymerase Chain Reaction in the Diagnosis of Toxoplasma Gondii
ChorioretinitisThomas Albini, 12:24 p.m. Collaborative Ocular Tuberculosis Study (COTS) Consensus Guidelines on
Initiating Antitubercular Therapy in Serpiginous Like ChoroiditisVishali Gupta 12:28 p.m. Post-Surgical Versus Post-Intravitreal Injection Endophthalmitis:
Changing Patterns in Causative FloraMatthew Simunovic 12:32 p.m. Discussion of Previous Three Papers 12:34 p.m. Effect of Intravitreal Sirolimus on Visual Acuity in Subjects with Active Non-infectious
Uveitis of the Posterior Segment of the Eye: Results of the SAKURA ProgramBrian Joodeph 12:43 p.m. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone
Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs.
INTravitreal Corticosteroids for Uveitic MacularMichael Altaweel 12:52 p.m. Suprachoroidally Injected CLS-TA Results in Rapid and Sustained Resolution of
Macular Edema in a Majority of Uveitis Patients: Results of the AZALEA,
DOGWOOD, and PEACHTREE StudiesSeenu Hariprasad 1:01 p.m. Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in
Noninfectious Uveitis: Results of the Phase 3 PEACHTREE StudySteven Yeh 1:04 p.m. Closing Remarks 1:10 p.m. Adjourn DeadlinesAbstract-Thema
01.01.1970Hinweis
-
Gebühren
Fachärzte/-innenGebühren abgebührenfreiÄrzte/-innen in WeiterbildungGebühren abgebührenfrei
-
Buchung / Anmeldung
Registration required. Please contact the organizer for further information.
-
Zertifizierung
Keine Zertifizierung beantragt
-
Sponsoren
Heidelberg Engineering Ltd
Notal Vision, Inc.
Bausch + Lomb
Novartis
Santen Inc. (USA)
Optos Inc. (USA)